Fletikumab (NNC0109-0012) is a monoclonal antibody targeting to IL-20. Fletikumab can be used for inflammation research, such as rheumatoid arthritis[1].
Fletikumab blocks IL-20 binding IL-20 receptor, acts potential function of inflammation inhibition[1].
IL-20 is a member of IL-10 family, which includes IL-10, IL-19, IL-22, IL-24, IL-26, IL-28, and IL-29. IL-20 acts on renal cells and contributes to inflammation, fibrosis, and apoptosis through its receptors IL-20R1, IL-20R2, and IL-22R1[2].
[1]. Kragstrup TW, et al. The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis. Front Immunol. 2018 Sep 25;9:2226.
[2]. Tian-Yu Lin, et al. IL-20 in Acute Kidney Injury: Role in Pathogenesis and Potential as a Therapeutic Target. Int. J. Mol. Sci.2020,21(3), 1009.